The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib

Publisher： Karger

E-ISSN： 1421-9662|134|1|57-58

ISSN： 0001-5792

Source： Acta Haematologica, Vol.134, Iss.1, 2015-04, pp. : 57-58

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Reduced Dose of Imatinib for Patients with Chronic Myeloid Leukemia and Low Body Surface Area

By  

Acta Haematologica, Vol. 118, Iss. 4, 2007-11 ,pp. : 219-221

Karger

Access to resources Recommend Favorite

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

By Saleh Mansoor N.   Haislip Sally   Sharpe Joyce   Hess Tamara   Gilmore James   Jackson James   Sail Kavita R.   Ericson Solveig G.   Chen Lei  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 529-536

Informa Healthcare

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Gelatinous Transformation of Bone Marrow in Chronic Myeloid Leukemia during Treatment with Imatinib Mesylate: A Disease or a Drug Effect?

By  

Acta Haematologica, Vol. 119, Iss. 2, 2008-03 ,pp. : 104-107

Karger

Access to resources Recommend Favorite

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

By Wu Eric Q.   Johnson Scott   Beaulieu Nicolas   Arana Mateo   Bollu Vamsi   Guo Amy   Coombs John   Feng Weiwei   Cortes Jorge  

Current Medical Research and Opinion, Vol. 26, Iss. 1, 2010-01 ,pp. : 61-69

Informa Healthcare

Access to resources Recommend Favorite